Drug Profile
Luspatercept - Acceleron Pharma/Celgene Corporation
Alternative Names: ACE-536; BMS-986346; Luspatercept-aamt; REBLOZYL; ReblozylLatest Information Update: 05 Apr 2024
Price :
$50
*
At a glance
- Originator Acceleron Pharma
- Developer Acceleron Pharma; Bristol-Myers Squibb; Celgene Corporation
- Class Antianaemics; Disulfides; Immunoglobulin Fc fragments; Peptides; Recombinant fusion proteins
- Mechanism of Action TGF-beta superfamily protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Beta-thalassaemia; Myelodysplastic syndromes
- Phase III Myelofibrosis
- Phase II Alpha-thalassaemia
- No development reported Sickle cell anaemia
Most Recent Events
- 02 Apr 2024 Registered for Myelodysplastic syndromes (Treatment-naive) in European Union, Liechtenstein, Norway, Iceland (SC)
- 23 Feb 2024 Committee for Medicinal Products for Human Use recommends approval of Luspatercept for Myelodysplastic syndromes in European Union
- 30 Jan 2024 Updated efficacy data from the phase II BEYOND trial in Beta-thalassaemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)